Betancourt FCE, Paque BC, Ávila GM, Solís HL, Monzón VML

Language: Spanish
References: 22
Page: 94-101
PDF size: 89.20 Kb.

ABSTRACT

Introduction: The route of administration of erythropoietin is controversial; several studies report more effective intravenously, while some mention that there is no difference, others support the subcutaneously. Objective: Know the effectiveness of erythropoietin administered subcutaneously and intravenously in the treatment of secondary anemia in pediatric patients with chronic renal failure HGOP UMAE 48. Clinical trials conducted in the UMAE N° 48 HGOP in the months of July-August 2008. Methodology: Of the total population of patients (51), were removed 13 and 38 were studied by simple random sampling were divided into two groups which were administered for two consecutive months erythropoietin intravenously or subcutaneously as appropriate. Blood sample was taken for each patient before treatment of hemodialysis at the start of the study and the two months following the intervention. Both groups will take an initial blood sample and one at the end of the study to determine levels of hemoglobin and to make the comparison. For the analysis of data using the statistical package SPSS 15.0 for Windows, and the Student t test to the statistical significance of a difference between two means. Results: There were no statistically significant results in the use of intravenous or subcutaneous erythropoietin. Discussion: The results obtained agree with those found by Pizarelli F in a study in Italy where it is mentioned that the route of administration of EPO has no effect on hemoglobin levels. Conclusion: Erythropoietin is effective in the treatment of anemia in pediatric hemodialysis patients regardless of route of administration.

REFERENCES

1. Harrison TR. Principios de medicina interna. 15ª edición México: McGraw-Hill, 2002; 2: 1815-1821.

2. Rivero S, Tanimoto WM. Uso de los medicamentos en la clínica. México D.F.: McGraw-Hill Interamericana, 1999: 273.

3. PLM Diccionario de especialidades farmacéuticas. 56 Edición México: Editores intersistemas, 2010; 1: 768.

4. Lacueva-Moya J, Antolín-Cariñena A, Santamaría C, Vicent-Bayarri C. Efectos beneficiosos del paso de gluconato férrico a hierro sacarosa sobre la anemia en hemodiálisis. DyT 2005; 26: 1: 19-26.

5. Pérez-Oliva J, Lagarde-Ampudia M, Herrera-Valdés R. Eficacia del tratamiento con eritropoyetina recombinante humana cubana (EPOCIM), en pacientes anémicos hemodializados. RNPS2034 ISSN1729-519X 2004; 3: 10.

6. Alfaro-Cuenca A, Beltrán-Redondo I, Gallego-Jordán B, García-García A, Romero-Espinoza E. Repercusión en nuestra unidad del cambio de vía de administración de Epoetinum Alfa. Rev Soc Esp Enferm Nefrol 2004; 7: 12-15.

7. Dar Santos AE, Shalansky, Jastrzebski JP. Management of anemia in erythropoietin-resistant hemodialysis patients. The annals of pharmacotherapy; 2003; 37: 1768-1773.

8. Muñoz J, Contreras D, Fernández R, Guisado C, Rivero F, Pérez J. Tolerancia a la diálisis en enfermos tratados con eritropoyetina. Revista Seden. Disponible en: http://www.revistaseden.org/files/tolerancia%20a%20ª%20diálisis%20en%20enfemos%20tratados%20con%20eritropoyetina.pdf.Google.Consultada el 21 de mayo del 2008 12 horas.

9. Blanco-Díaz A, Pérez-Oliva J, López-Perez M, Marrero-García M, Sánchez-Díaz J, Santamaría-Trujillo C. Eritropoyetina recombinante humana en la insuficiencia renal crónica. Revista Cubana Médica Milit 2003; 32.

10. Moist L, Muirhead N, Wazny LD, Kerry Gallo L, Heidenheim AP, House AA. Erythropoietin dose requirements when converting from subcutaneous to intravenous. The Annals of Pharmacotherapy 2006; 40: 198-203.

11. Cody J et al. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes prediálisis. Revisiones Cochrane 2007. Biblioteca Cochrane Plus (ISSN 1745-9990).

12. Pizarelli F, David S, Sala P, Icardi A, Casani A. Iron-replete hemodyalisis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of Italia Study on erythropoietin converting. Am J Kidney Dis 2006; 47: 1027-35.

13. Malovrh M, Premru V. Subcutaneous compared with intravenous epoetin treatment in patients on hemodyalisis: one center study. Ther Apher Dial 2005; 9: 233-236.

14. Bruce AP, Rowan W. Dose of epoetin alfa used in haemodyalisis patients when switching from subcutaneous administration. Nefrology 2007; 12 (2): 120-125.

15. Molina M, García H, Navarro MJ, De Gracia MC, Ortuño T. Estudio comparativo sobre el tratamiento de la anemia renal en el paciente en hemodiálisis: cambio de vía de administración de epoetina alfa frente a conversión a darbepoetina. Nefrología 2004; 24 (6): 564-569.

16. Anatole B, Reyes CM, Hornberger J. Meta-analysis of subcutaneous vs intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. American Journal of Kidney Diseases 2002; 40 (3): 439-446.

17. Rodríguez JR, Ruiz E, Vázquez G, Ruiz CE. Repercusiones clínicas y económicas del cambio de vía de administración de Eritropoyetina. Nefrología 2005; 25: 343-344.

18. Linde T, Furuland H, Wikström B. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodyalisis patients results from a Swedish multicentre survey. Scand J Urology Nephrology 2005; 39: 329-33.

19. Barre P, Reichel H, Suranyi MG, Barth C. Efficacy of once-weekly epoetin alfa. Clinic Nephrology 2004; 62 (6): 440-8.

20. Murray JL, Kent AB, Gavin JB, Mcmahon LP. Haemoglobin response to subcutaneous vs intravenous epoetin alfa admistration in iron replete haemodyalisis patients 2004; 9 (3): 153-160.

21. http://www.uchile.cl/bioetica/doc/normas.htm. Normas éticas para la investigación clínica Mancini R. Consultor Programa Regional de Bioética, OPS/OMS. ©CIEB 2000. Disponible en Google, consultado 27 de mayo del 2008.

22. http://www.wma.net/s/policy/b3.htm. Declaración de Helsinki de la Asociación Médica Mundial, Principios éticos para las investigaciones médicas en seres humanos. World Medical Association. Disponible en Google, consultado el 27 de mayo del 2008.